Incyte’s Ruxolitinib Cream Shows Promise for Vitiligo in Phase III Trials Published: May 17, 2021 By Brandon May

The use of ruxolitinib cream, Incyte’s investigational anti-inflammatory JAK inhibitor topical treatment, significantly improved facial vitiligo in adolescents and adults, according to topline results from two pivotal Phase III clinical trials.